Brain Cancer Patients Display Appropriate Immune Responses and Decreasing Tumor Biomarkers in AIVITA Biomedical’s Phase 2 Clinical Trial
IRVINE, Calif., Oct. 24, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated data from its ongoing glioblastoma Phase 2 clinical trial investigating AIVITA’s platform immunotherapy targeting tumor-initiating cells. In approximately 80% of treated patients, sequential blood plasma biomarker analyses have identified the induction of a […]